Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average - Here's Why

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.53 and traded as high as $4.59. Cumberland Pharmaceuticals shares last traded at $4.40, with a volume of 118,912 shares changing hands.

Analyst Ratings Changes

Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, March 6th.

Cumberland Pharmaceuticals Stock Performance

The company's 50-day moving average price is $4.47 and its two-hundred day moving average price is $2.58. The company has a market cap of $61.60 million, a P/E ratio of -5.73 and a beta of -0.18. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. The business had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Remove Ads

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP increased its stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,649 shares of the specialty pharmaceutical company's stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent filing with the Securities and Exchange Commission. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.